NDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
GABITRIL (tiagabine hydrochloride) by Teva is mechanism of action the precise mechanism by which tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability, documented in in vitro experiments, to enhance the activity of gamma aminobutyric acid (gaba), the major inhibitory neurotransmitter in the central nervous system. First approved in 1997.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GABITRIL (tiagabine hydrochloride) is an oral antiseizure agent approved for generalized anxiety disorder that enhances GABA activity by blocking its reuptake into presynaptic neurons, allowing more GABA to bind to post-synaptic receptors. The mechanism involves selective inhibition of the GABA uptake carrier, distinguishing it from benzodiazepines and other CNS modulators. Originally developed as an antiepileptic, it has been repositioned for anxiety indication.
$0.728MPart D
LOE ApproachingDeclining
Product faces patent expiration with minimal current Medicare utilization, indicating reduced brand investment and smaller commercial team focus.
Mechanism of Action
Mechanism of Action The precise mechanism by which tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability, documented in in vitro experiments, to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the…
Worked on GABITRIL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.